OncoTargets and Therapy (May 2021)
Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report
Abstract
Qian Li,1 Wei Liu,2 Kai Li,3 Yifu Tian,4 Huan Li2 1Lung Hospital, Changsha Central Hospital, University of South China, Changsha, Hunan Province, People’s Republic of China; 2Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People’s Republic of China; 3Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People’s Republic of China; 4Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People’s Republic of ChinaCorrespondence: Huan LiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People’s Republic of ChinaTel +8615116337538Email [email protected]: Non-Hodgkin lymphoma can disseminate to the central nervous system at initiation of treatment for systemic lymphoma or spread during the relapse of systematic lymphoma with CNS involvement, which is defined as secondary central nervous system lymphoma (SCNSL). The incidence of SCNSL depends on the pathological type of lymphoma and is especially high in aggressive lymphoma. SCNSL has a poor prognosis because of the lack of effective treatment regimens. This article presents a rare case of SCNSL; an individualized treatment regimen was designed according to the genetic analyses of the patient tumor and included a Bruton’s tyrosine kinase (BTK) inhibitor. After six cycles of treatment and another two cycles of rituximab, most lesions lost their metabolic activity. However, in the final stage of treatment, our patient unfortunately suffered from respiratory failure, which revealed that we should pay attention to Pneumocystis jirovecii pneumonia during ibrutinib treatment.Keywords: secondary central nervous system lymphoma, diffuse large B cell lymphoma, ibrutinib, individualized therapy, Pneumocystis jirovecii pneumonia
